Biocartis

20/02/2026

𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲*
✅ Molecular classification of samples in ~ 95 min.
✅ Covers 99% of the known pathogenic & mutations
✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024)
✅ Fit for use on small biopsies & directly from 1 FFPE tissue section
✅ No need for sample batching
✅ Straightforward results reporting

👉 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay?utm_source=facebook&utm_medium=social&utm_campaign=2002_mutation-assay

*For Research Use Only (RUO), not for use in diagnostic procedures.
Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting

18/02/2026

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf


*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

18/02/2026

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸, 𝘄𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗠𝗣𝗔𝗜𝗖𝗢𝗡 𝟮𝟬𝟮𝟲!
📅 26-28 February |📍Booth 21 | 🗺️ Kolkata, India

Come meet Mashood at booth 21 and learn more about getting your molecular biomarker results in only 3 hours with Idylla™ ⏱️

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en/news-events/events/mpaicon-2026

16/02/2026

💡 Let's start innovating together!

Biocartis’ mission is to ensure patients and their physicians have access to the right test results at the right time to deliver the right treatment.

Interested to partner with us for a companion diagnostic?

Contact our pharma partnering team 👉 https://www.biocartis.com/en/partnering/partnering-contact?utm_source=facebook&utm_medium=social&utm_campaign=1602_partnering-contact

Connect with us at [email protected] or use the form below to get in touch. Contact us You must have JavaScript enabled to use this form. First name Last name Email Phone Company / Organisation / Institute Country / region Where did you hear about us? Message For information about the processing of...

14/02/2026

We 💙 our Idylla™ 😍 How about you?
Happy Valentine’s day and lovely wishes from the Biocartis Team!
Meet Idylla™ 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1402_meet-idylla

12/02/2026

Molecular biomarker results in ONLY 3 HOURS!
💡 THINK IDYLLA™

Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer.

More information 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1202_meet-idylla

11/02/2026

A research study (Iorgulescu et al., 2025), conducted at MD Anderson Cancer Center, demonstrated the 𝗳𝗲𝗮𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗼𝗳 𝘀𝗮𝗺𝗲-𝗱𝗮𝘆 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝘀𝗼𝗹𝗶𝗱 𝘁𝘂𝗺𝗼𝗿 𝗰𝘆𝘁𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 using the ™ Platform 👏

The study illustrated the potential of Idylla™’s automated, cartridge-based PCR assays to deliver 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝗼𝗻𝗹𝘆 𝟮–𝟯 𝗛𝗢𝗨𝗥𝗦 of specimen collection, 𝗱𝗶𝗿𝗲𝗰𝘁𝗹𝘆 𝘄𝗶𝘁𝗵𝗶𝗻 𝘁𝗵𝗲 𝗰𝘆𝘁𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 𝗹𝗮𝗯.

𝗞𝗘𝗬 𝗙𝗜𝗡𝗗𝗜𝗡𝗚𝗦
✅Accurate detection of KRAS, EGFR, BRAF, and gene fusions with concordance of 94–100% with comparator methods
✅Enables fast, in-house testing with minimal sample requirements
✅Provides a framework for integrating rapid molecular testing into cytopathology workflows, allowing for additional NGS testing when needed

👀 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://pubmed.ncbi.nlm.nih.gov/39746874/
🔎 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝗜𝗱𝘆𝗹𝗹𝗮™: https://www.biocartis.com/en/meet-idylla

06/02/2026

𝗥𝗘𝗩𝗜𝗦𝗜𝗧 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: Translating new clinical insights into better outcomes: The role of biomarker testing in mCRC

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- Treatment landscape of mCRC patients
- Key insights from the Checkmate-8HW clinical trial
- The Idylla™ CDx MSI Test and its fully automated workflow

👉 𝗪𝗮𝘁𝗰𝗵 𝗻𝗼𝘄: https://lnkd.in/eEB5D5kp



𝙏𝙝𝙞𝙨 𝙬𝙚𝙗𝙞𝙣𝙖𝙧 𝙞𝙨 𝙞𝙣𝙩𝙚𝙣𝙙𝙚𝙙 𝙛𝙤𝙧 𝙐𝙎 𝙖𝙪𝙙𝙞𝙚𝙣𝙘𝙚𝙨 𝙤𝙣𝙡𝙮.
Idylla™ CDx MSI Test (A0220/6) is approved in the US under P250005.

04/02/2026

🩵𝐄𝐯𝐞𝐫𝐲 𝐜𝐚𝐧𝐜𝐞𝐫 𝐣𝐨𝐮𝐫𝐧𝐞𝐲, 𝐞𝐯𝐞𝐫𝐲 𝐩𝐚𝐭𝐢𝐞𝐧𝐭, 𝐞𝐯𝐞𝐫𝐲 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐢𝐬 𝐮𝐧𝐢𝐪𝐮𝐞.
Behind every test result is a person waiting for answers, each with their own story, their own cancer, their own treatment path.

This World Cancer Day, we stand , bringing personalized medicine closer to patients worldwide with 𝐈𝐝𝐲𝐥𝐥𝐚™, so 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 can reflect what makes 𝐞𝐚𝐜𝐡 𝐜𝐚𝐬𝐞 𝐮𝐧𝐢𝐪𝐮𝐞.
👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=0402_meet-idylla

02/02/2026

💡𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 𝗮 𝗳𝗮𝘀𝘁, 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘄𝗮𝘆 𝘁𝗼 𝗱𝗲𝘁𝗲𝗰𝘁 𝗣𝗜𝗞𝟯𝗖𝗔 & 𝗔𝗞𝗧𝟭 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀?

Discover the 𝗨𝗣𝗗𝗔𝗧𝗘𝗗 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗜𝗞𝟯𝗖𝗔-𝗔𝗞𝗧𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆:
✅ 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗰𝗼𝘃𝗲𝗿𝗮𝗴𝗲: Detection of 13 PIK3CA mutations and 1 AKT1 mutation
✅ 𝗠𝗶𝗻𝗶𝗺𝗮𝗹 𝘀𝗮𝗺𝗽𝗹𝗲 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: Directly from 1 FFPE tissue section (5 - 10 µm) with hands-on time under 3 minutes
✅ 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄: Single-use cartridge, cost-effective, no batching required
✅ 𝗣𝗿𝗼𝘃𝗲𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆: 97% overall concordance versus NGS and real-time PCR tests*

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en/research/research-assays/idylla-pik3ca-akt1-mutation-assay-0?utm_source=facebook&utm_medium=social&utm_campaign=0202_mutation-assay


For Research Use Only (RUO), not for use in diagnostic procedures.

30/01/2026

💡𝗢𝗣𝗗𝗜𝗩𝗢® (𝗻𝗶𝘃𝗼𝗹𝘂𝗺𝗮𝗯) 𝗽𝗹𝘂𝘀 𝗬𝗘𝗥𝗩𝗢𝗬® (𝗶𝗽𝗶𝗹𝗶𝗺𝘂𝗺𝗮𝗯) 𝘄𝗮𝘀 𝗙𝗗𝗔-𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 as a new 1L ICI option for MSI-H/dMMR mCRC patients based on outcomes from the CheckMate-8HW trial(1,2)

In CheckMate-8HW, the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁 was used to establish the primary endpoints, revealing 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 compared with local testing, as reflected in both the hazard ratio (0.20 vs 0.32) and ORR (74% vs 64%) (2)

🔍This analysis indicates that the 14% discordance rate between Idylla™ and locally obtained dMMR/MSI-H results was due to false positives from the local testing method - 𝗺𝗶𝘀𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗵𝗮𝘁 𝗹𝗶𝗸𝗲𝗹𝘆 𝗱𝗶𝗹𝘂𝘁𝗲𝗱 𝘁𝗵𝗲 𝗼𝗯𝘀𝗲𝗿𝘃𝗲𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆.

👉 The Idylla™ CDx MSI Test is an accurate diagnostic solution that supports precision medicine at its best: ensuring the right patient receives the right treatment for the best possible outcomes. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test


Approved in the US under P250005. OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company.
(1) https://doi.org/10.1056/NEJMoa2402141; https://doi.org/10.1016/S0140-6736(24)02848-4;
(2) https://doi.org/10.1200/JCO.2025.43.16_suppl.3501

29/01/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆
⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy.

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay.

👉 Read morehttps://www.biocartis.com/sites/default/files/2024-09/colorectal-leaflet-august2024.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡


*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.